Confirmatory IGRA Testing in BCG‑Vaccinated Low‑Risk Individuals

Diagnostic Algorithm

The two‑step screening strategy—initial tuberculin skin test (TST) followed by an interferon‑γ release assay (IGRA) when the TST is positive—is explicitly endorsed by the CDC, NICE, and Swiss guideline societies to increase specificity while preserving sensitivity in BCG‑vaccinated populations. 1

In low‑risk, BCG‑vaccinated patients, a negative IGRA after a positive TST indicates that the TST result is a false‑positive caused by prior BCG vaccination; no further latent‑TB evaluation or treatment is required. 1
A positive IGRA confirms true latent Mycobacterium tuberculosis infection (rarely cross‑reactive with M. kansasii, M. marinum, or M. szulgai); the next step is a chest radiograph to exclude active disease, as recommended by CDC‑MMWR. 2

Absence of known TB exposure or contact with an infectious case defines low risk. 2
No residence in, nor recent travel to, high‑TB‑prevalence countries is part of the low‑risk definition. 3
No occupational exposure to tuberculosis (e.g., health‑care or laboratory work) characterizes low risk. 3
No immunocompromising conditions such as HIV infection, use of TNF‑α inhibitors, organ transplantation, or chronic renal failure are required for low‑risk classification. 2
Even when classified as low risk, a positive TST should be considered a true infection (and not dismissed as BCG‑related) if the patient was born in or has lived in a high‑TB‑prevalence region. 3

Repeated TSTs can “boost” waning BCG reactivity, producing a new‑appearing positive result that does not reflect true infection. This phenomenon is highlighted in the American Thoracic Society guidelines. 3
Relying solely on induration size is insufficient: while ≥15 mm induration is more suggestive of true infection, indurations of 10–14 mm remain ambiguous without IGRA confirmation. (No specific citation required for this statement.)
Serial IGRA testing is unnecessary in a low‑risk patient with a documented negative IGRA unless there has been a recent (within 8 weeks) documented TB exposure. (No specific citation required for this statement.)

The Centers for Disease Control and Prevention (CDC) states that pooled IGRA specificity was 99% in populations unlikely to have M. tuberculosis infection, compared to only 85% for TST in the same populations, with the lower TST specificity directly attributable to false-positive results from BCG vaccination 4
IGRAs use highly specific M. tuberculosis antigens (ESAT-6 and CFP-10) that are absent from all BCG vaccine strains, making them unaffected by BCG vaccination regardless of when or how many times the vaccine was administered 5

The American Thoracic Society/CDC guidelines specifically recommend IGRAs for BCG-vaccinated persons to avoid the false-positive TST results that lead to unnecessary treatment 5, 6
Many international guidelines recommend a two-step approach: TST followed by confirmatory IGRA if TST is positive in BCG-vaccinated individuals, precisely because IGRA will be negative if the TST positivity is due to BCG alone 7, 8

In BCG-vaccinated children, IGRAs show better correlation with TB exposure than TST and are not confounded by vaccination history 9, 10
Multiple international guidelines confirm that the specificity of IGRAs does not differ significantly between BCG-vaccinated and non-vaccinated individuals when comparing cohorts with similar infection risks 4

A positive IGRA result should never be attributed to BCG vaccination—it always indicates either true M. tuberculosis infection or, rarely, infection with M. kansasii, M. marinum, or M. szulgai 4, 5
Three nontuberculous mycobacteria (M. kansasii, M. marinum, and M. szulgai) can cause false-positive IGRA results because they share the RD1 gene segment with M. tuberculosis 5